Anti-mesothelin antibodies
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.
1. An antibody that specifically binds to mesothelin and is capable of both eliciting an immune effector activity and internalizing within mesothelin-positive cells, said antibody comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 4 absent amino acids 1 to 19 thereof; a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 6 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8 absent amino acids 1 to 19 thereof; or a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 10 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 12 absent amino acids 1 to 19 thereof.
2. The antibody of claim 1 , wherein the immune effector activity is antibody dependent cellular cytotoxicity.
3. The antibody of claim 1 , wherein the immune effector activity is complement dependent cytotoxicity.
4. The antibody of claim 1 , wherein said antibody is conjugated to a chemotherapeutic agent.
5. The antibody of claim 4 wherein said chemotherapeutic agent comprises a radionuclide.
6. A kit comprising the antibody of claim 1 , and instructions for using the kit in a method for inhibiting the growth of tumor cells in a subject.
7. The kit of claim 6 further comprising at least one chemotherapeutic or cytotoxic reagent.
8. The kit of claim 6 further comprising at least one diagnostic reagent.
9. The kit of claim 6 further comprising means and instructions for administering the antibody to the subject.
10. A kit comprising the antibody of claim 1 , and instructions for using the kit in a method for identifying the presence of mesothelin-positive dysplastic cells in vitro or in vivo.
11. The kit of claim 10 further comprising at least one diagnostic reagent.
12. An antibody that specifically binds to mesothelin produced by recombinantly expressing in a cell the nucleic sequence of SEQ ID NO: 1 and the nucleic acid sequence of SEQ ID NO: 3, the nucleic acid sequence of SEQ ID NO: 5 and the nucleic acid sequence of SEQ ID NO: 7, or the nucleic acid sequence of SEQ ID NO: 9 and the nucleic acid sequence of SEQ ID NO: 11.
13. The antibody of claim 12 wherein said antibody is recovered from the growth medium of said cell.
14. The antibody of claim 12 wherein said cell is a mammalian cell.